DGAP-News: NASDAQ Welcomes GW Pharmaceuticals to The NASDAQ Stock Market
(firmenpresse) - The NASDAQ OMX Group, Inc.
01.05.2013 18:07
---------------------------------------------------------------------------
NEW YORK, 2013-05-01 18:07 CEST (GLOBE NEWSWIRE) --
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today that trading of GW
Pharmaceuticals (Nasdaq:GWPH), a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from its
cannabinoid product platform, commenced on The NASDAQ Stock Market on May 1,
2013.
GW is a biopharmaceutical company at the forefront of plant-derived cannabinoid
therapeutics. In its 14 years of operations, the company has established a
world leading position in the development of prescription cannabinoid medicines
through its proven drug discovery and development processes, intellectual
property portfolio and regulatory and manufacturing expertise. GW
commercialized the world's first plant-derived cannabinoid prescription drug,
Sativex(r), which is approved for the treatment of spasticity due to multiple
sclerosis in 20 countries outside of the United States. Sativex is also in
Phase III clinical development for the treatment of cancer pain, the lead
indication for the U.S. market and the company anticipates top-line results
from the first of two Phase 3 trials will be available in mid-2014. GW has a
deep pipeline of additional cannabinoid product candidates, including two
distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for
Type 2 diabetes and ulcerative colitis, respectively.
'Through its product Sativex and broad pipeline, GW Pharmaceuticals has
established itself as the world leader in cannabinoid science,' said Nelson
Griggs, Senior Vice President, NASDAQ OMX. 'GW truly exemplifies the type of
groundbreaking and innovative pharmaceutical company that partners with NASDAQ
and we are proud to welcome them on our exchange.'
Since its inception, NASDAQ OMX has consistently been the exchange of choice
for progressive and cutting-edge health care and pharmaceutical companies like
GW Pharmaceuticals. NASDAQ is currently home to more than 420 healthcare
companies representing 73 percent of all U.S. listed companies in the sector,
including industry-leading pharmaceutical companies such as Amgen Inc, Gilead
Sciences Inc., Celgene Corp. and Biogen Idec Inc.
About NASDAQ OMX
The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels
economies and provides transformative technologies for the entire lifecycle of
a trade - from risk management to trade to surveillance to clearing. In the
U.S. and Europe, we own and operate 26 markets including 3 clearinghouses and 5
central securities depositories supporting equities, options, fixed income,
derivatives, commodities, futures and structured products. Able to process more
than 1 million messages per second at sub-55 microsecond average speeds with
99.99% uptime, our technology drives more than 70 marketplaces in 50 developed
and emerging countries into the future, powering 1 in 10 of the world's
securities transactions. Our award-winning data products and worldwide indexes
are the benchmarks in the financial industry. Home to approximately 3,300
listed companies worth $6 trillion in market cap whose innovations shape our
world, we give the ideas of tomorrow access to capital today. Welcome to where
the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century.
To learn more, visit www.nasdaqomx.com. Follow us on Facebook
(http://www.facebook.com/NASDAQ) and Twitter
(http://www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500)
The information contained above is provided by The NASDAQ OMX Group, Inc. for
informational and educational purposes only, and nothing contained herein
should be construed as investment advice, either on behalf of a particular
security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc.
nor any of its affiliates makes any recommendation to buy or sell any security
or any representation about the financial condition of any company. Statements
regarding NASDAQ-listed companies are not guarantees of future performance.
Actual results may differ materially from those expressed or implied. Past
performance is not indicative of future results. Investors should undertake
their own due diligence and carefully evaluate companies before investing.
ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
NDAQG
CONTACT: Jennifer Knapp
+1 212 401 8916
Jennifer.Knapp(at)nasdaqomx.com
News Source: NASDAQ OMX
01.05.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: The NASDAQ OMX Group, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US6311031081
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.05.2013 - 18:07 Uhr
Sprache: Deutsch
News-ID 255120
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 270 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: NASDAQ Welcomes GW Pharmaceuticals to The NASDAQ Stock Market"
steht unter der journalistisch-redaktionellen Verantwortung von
The NASDAQ OMX Group, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
